IPCA Laboratories Limited

IPCA Laboratories Limited

Ipca Laboratories Limited has reported Q1 FY27 earnings, with its domestic formulation business growing 13% to INR1,082 crores, and export business growing 34% to INR603 crores. The company has also seen an improvement in EBITDA margins, with consolidated EBITDA margins improving to 22.88% and standalone EBITDA margins improving to 26%. The company has outperformed the market in both chronic and acute segments.

IPCA Laboratories Limited

IPCA Laboratories Limited has informed the Exchange about the link to the recording of their conference call held on August 14, 2026, to discuss Q1FY27 earnings and business update.

IPCA Laboratories Limited

IPCA Laboratories Limited has published its unaudited financial results for the first quarter ended June 30, 2026, showing a net profit of Rs. 4.08 lakhs and a basic earnings per share of Rs. 0.08.

IPCA Laboratories Limited

IPCA Laboratories Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 13, 2026, and informed the Exchange regarding voting results. All resolutions were passed by requisite majority.

IPCA Laboratories Limited

IPCA Laboratories Limited held its 76th Annual General Meeting on August 13, 2026, through video conferencing. The meeting approved the adoption of audited financial statements, dividend payment, and the appointment of new directors. The meeting also ratified the remuneration payable to cost auditors and re-appointed the executive director.

IPCA Laboratories Limited

IPCA Laboratories Limited has announced its unaudited standalone financial results for the quarter ended June 30, 2026, with revenue from operations at ₹2,119.24 crores and profit for the period from continuing operations at ₹373.29 crores.

IPCA Laboratories Limited

IPCA Laboratories Limited has informed the Exchange about a Conference Call to discuss the Company’s Q1FY27 earnings and business update.

IPCA Laboratories Limited

IPCA Laboratories Limited has informed the Exchange regarding the intimation to non-email cases regarding the weblink of Annual Report. The company has issued letters to shareholders whose e-mail addresses are not registered with the Company/Depository/Registrar and Share Transfer Agent, providing the web-link from where the Annual Report can be accessed.

IPCA Laboratories Limited

IPCA Laboratories Limited has informed the Exchange about the notice of its 76th Annual General Meeting (AGM) and e-voting details published in the newspapers.

IPCA Laboratories Limited

IPCA Laboratories Limited has announced the record date for the purpose of dividend as 07-Aug-2026.

IPCA Laboratories Limited

IPCA Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 13, 2026, where the Board has recommended a dividend of Rs. 6/- per share for the financial year ended 31st March, 2026.

IPCA Laboratories Limited

IPCA Laboratories Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report' for the financial year 2025-26.

IPCA Laboratories Limited

IPCA Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialisation of securities during the quarter ended June 30, 2026.

IPCA Laboratories Limited

IPCA Laboratories Limited has informed the Exchange about the affirmation of credit ratings by India Ratings & Research for the company's working capital limit, long-term loan, and commercial paper. The ratings are IND A1+ for commercial paper and IND AA+/ Stable for bank loan facilities.

IPCA Laboratories Limited

Ipca Laboratories Limited has informed the Exchange about a copy of newspaper publication regarding the 76th Annual General Meeting (AGM) and other related matters.

IPCA Laboratories Limited

Ipca Laboratories Limited has approved the Scheme of Amalgamation of Krebs Biochemicals & Industries Ltd. with the company, subject to necessary approvals. The amalgamation aims to result in operational synergies, cost optimization, and increased business through consolidation of business and access to new manufacturing capabilities.

IPCA Laboratories Limited

Ipca Laboratories Limited has approved the Scheme of Amalgamation of Krebs Biochemicals & Industries Ltd. with the Company under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.

IPCA Laboratories Limited

IPCA Laboratories Limited announced the closure of its trading window for insiders, effective from July 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and will remain in effect until 48 hours after the declaration of the unaudited financial results for the first quarter ended June 30, 2026. The date of the Board meeting for considering these results will be intimated later.